Azathioprine for first attack in MOG antibody disease
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy, Infections clinical trials.
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You had a first attack of brain/spinal cord inflammation within the last 3 months.
- A test shows MOG antibodies (MOG-Ab positive) from the study’s central lab.
- You can understand the study and sign consent (and your healthcare coverage is in place).
- If you could become pregnant: use effective birth control during treatment and for at least 3 months after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This Phase 3 trial tests whether starting anti-inflammatory treatment right away is better than waiting, using either azathioprine or rituximab, for children with anti-MOG antibody–related acute demyelinating episodes. It may help reduce future attacks and disability.
This study is testing two new blood tests to see if they can better diagnose MOGAD, an inflammatory condition that affects the brain and spinal cord. If you or your doctor suspects MOGAD, this trial may help confirm the diagnosis.
This trial tests a new medicine called inectolizumab, combined with optimized steroid therapy, for people having their first attack of neuromyelitis optica spectrum disorder (NMOSD). The goal is to see if this combination better controls the disease and prevents future attacks.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
Hear when a new Central Nervous System Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.